Wed, 22 Apr 2026 15:55:19 -0400 http://joemullings.com en-us © 2026 Joe Mullings Untitled yes 713ffccb-7492-549f-8870-02094978e943 Joe Mullings episodic false The Untitled Podcast is designed to get you to think. Not what to think, but think. We cover subjects in healthtech, medtech, personal performance, and leadership.

]]> Buzzsprout (https://www.buzzsprout.com) Joe Mullings https://storage.buzzsprout.com/z5auew645rk68e4nuwmz7fewusiu?.jpg http://joemullings.com Joe Mullings Bringing Your Medtech Startup to the U.S. One of the most critical decisions an Outside the United States (OUS) medical device company will make is when should they come to the U.S. and who should be their first hire and typically fast follow hires after that? Historically, hiring that first person in the U.S. has had less than desirable outcomes for most companies and Joe discusses how to guard against that and the best way to have a successful result.

]]> One of the most critical decisions an Outside the United States (OUS) medical device company will make is when should they come to the U.S. and who should be their first hire and typically fast follow hires after that? Historically, hiring that first person in the U.S. has had less than desirable outcomes for most companies and Joe discusses how to guard against that and the best way to have a successful result.

]]> Joe Mullings Buzzsprout-16431252 Wed, 20 Nov 2024 00:00:00 -0500 682 1 9 full false Acquisitions & Name Changes – What is the Cultural Impact? The integration of acquisitions of high performing organizations continues to have less than ideal outcomes as you track those acquisitions a few years down range. One of the dynamics in nearly all acquisitions is the dilution of the culture, brand, and native mindset of the company that was so valuable, that is merited being acquired for a premium. The discussion of the recent Johnson & Johnson acquisitions of Shockwave and Abiomed is examined here.

]]> The integration of acquisitions of high performing organizations continues to have less than ideal outcomes as you track those acquisitions a few years down range. One of the dynamics in nearly all acquisitions is the dilution of the culture, brand, and native mindset of the company that was so valuable, that is merited being acquired for a premium. The discussion of the recent Johnson & Johnson acquisitions of Shockwave and Abiomed is examined here.

]]> Joe Mullings Buzzsprout-16431241 Mon, 18 Nov 2024 00:00:00 -0500 849 1 8 full false OUS Robotics Coming to the US with Steve Bell Joe & Steve Bell discuss surgical robotics, more specifically the companies building a robot outside of the US who have begun the journey to participate in the US market. With many robots in development currently, the road to the US is critical to gaining momentum and market share. The micro and macro differences in how engineers globally approach designing a robot are already coming to light. Differentiators and solving existing problems for surgeons will be key in the race to access the US market.

]]> Joe & Steve Bell discuss surgical robotics, more specifically the companies building a robot outside of the US who have begun the journey to participate in the US market. With many robots in development currently, the road to the US is critical to gaining momentum and market share. The micro and macro differences in how engineers globally approach designing a robot are already coming to light. Differentiators and solving existing problems for surgeons will be key in the race to access the US market.

]]> Joe Mullings Buzzsprout-15807506 Fri, 26 Jul 2024 08:00:00 -0400 1552 1 7 full false Robotics Update with Steve Bell Joe and Steve discuss the rapidly evolving dynamics of the soft tissue surgical robotics markets and what moves some of the current form factors and companies are committing to. 

]]> Joe and Steve discuss the rapidly evolving dynamics of the soft tissue surgical robotics markets and what moves some of the current form factors and companies are committing to. 

]]> Joe Mullings Buzzsprout-15469549 Wed, 15 May 2024 08:00:00 -0400 1164 1 6 full false Steve Bell on the Intuitive Da Vinci 5 Intuitive released the DaVinci 5 platform and it is creating a higher bar in the soft tissue surgical robotic market. Joe and Steve discuss how the table stakes for surgical robotics has been leveled up with the D5 platform. 

]]> Intuitive released the DaVinci 5 platform and it is creating a higher bar in the soft tissue surgical robotic market. Joe and Steve discuss how the table stakes for surgical robotics has been leveled up with the D5 platform. 

]]> Joe Mullings Buzzsprout-15469511 Fri, 05 Apr 2024 08:00:00 -0400 1679 1 5 full false Tony Blauer on Managing Fear in a Career Tony Blauer wrote the book on the Management of Fear in Combat Sports as well as violent encounters. His body of work is even more applicable in the business world. Joe and Tony discuss how fear management and the control of our emotions can be the difference maker in success and failure. 

]]> Tony Blauer wrote the book on the Management of Fear in Combat Sports as well as violent encounters. His body of work is even more applicable in the business world. Joe and Tony discuss how fear management and the control of our emotions can be the difference maker in success and failure. 

]]> Joe Mullings Buzzsprout-15469484 Fri, 01 Mar 2024 08:00:00 -0500 1818 1 4 full false Steve Bell on Exploring Endovascular Robots and The Market Steve and Joe discuss the emerging market of endovascular robotics and how it sets up to be a bigger market than soft tissue robotics and enabled by quicker development times, less cost, and more acquirers in the market. 

]]> Steve and Joe discuss the emerging market of endovascular robotics and how it sets up to be a bigger market than soft tissue robotics and enabled by quicker development times, less cost, and more acquirers in the market. 

]]> Joe Mullings Buzzsprout-15469393 Thu, 22 Feb 2024 08:00:00 -0500 2719 1 3 full false Mike Minogue on Leadership and Abiomed Joe and Mike Minogue, the recent CEO of Abiomed which was sold to Johnson & Johnson for $16 billion discuss some of the principles and the mindset of how to build high performing teams and enable success. 

]]> Joe and Mike Minogue, the recent CEO of Abiomed which was sold to Johnson & Johnson for $16 billion discuss some of the principles and the mindset of how to build high performing teams and enable success. 

]]> Joe Mullings Buzzsprout-15469386 Tue, 30 Jan 2024 08:00:00 -0500 2277 1 2 full false Soft Tissue Robotics Market with Steve Bell In the inaugural episode of Joe Mullings Untitled, Steve Bell and Joe Mullings discuss the emerging trends, industry dynamics, the changing centers of care, and where the soft tissue surgical robotic market and technologies are likely going.

]]> In the inaugural episode of Joe Mullings Untitled, Steve Bell and Joe Mullings discuss the emerging trends, industry dynamics, the changing centers of care, and where the soft tissue surgical robotic market and technologies are likely going.

]]> Joe Mullings Buzzsprout-15435658 Thu, 11 Jan 2024 08:00:00 -0500 2958 1 1 full false